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G-protein-coupled receptors (GPCRs) are frequent and fruit-
ful targets for drug discovery and development, as well as being
off-targets for the side effects of a variety of medications. Much
of the druggable non-olfactory human GPCR-ome remains
under-interrogated, and we present here various approaches
that we and others have used to shine light into these previously
dark corners of the human genome.
G-protein-coupled receptors (GPCRs;2 7-transmembrane
domain receptors) historically have represented both the
most abundant and the most popular gene superfamily for
therapeutic drug discovery and development, with perhaps
30 – 40% of approved drugs targeting the non-olfactory
GPCRs (1, 2). Typical estimates are that, at any given time,
between 20 and 40% of candidate medications target non-
olfactory GPCRs as their canonical or principal molecular
targets (2– 4). Indeed, in 2014, of the 41 new molecular enti-
ties approved by the Food and Drug Administration (FDA)
(http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
DrugInnovation/ucm20025676.htm), 9 had GPCRs as their
canonical sites of action (Table 1). Of the GPCRs targeted by
known drugs, the Family A aminergic GPCRs are by far the
most popular (2– 4) with aripiprazole, which has multiple
biogenic amine GPCR targets and a complex mode of action
(5), being the bestseller in 2014. As the olfactory GPCRs do
not yet represent therapeutic targets, we will focus on the
non-olfactory GPCRs here.
Not only do GPCRs represent the principal therapeutic site
of action of many approved and candidate medications, but
GPCRs also represent prominent “off-targets” for severe and
potentially life-threatening side effects. Of these, drugs with
5-HT2B serotonin receptor agonism have long been docu-
mented to induce severe, life-threatening valvular heart disease
(6 – 8). Indeed, based on the potent 5-HT2B agonist activity of
certain ergot derivatives used in treating Parkinson disease and
migraine headaches (e.g. pergolide, cabergoline, and dihydroer-
gotamine), we correctly predicted that these medications
would also induce valvular heart disease (7, 8). Two of these
drugs (pergolide and cabergoline) were withdrawn from the
international market following large-scale trials demonstrating
their life-threating side effects (8, 9). In follow-up studies, we
surveyed 2200 FDA-approved and investigational medications,
finding that 27 had potentially significant 5-HT2B agonism, of
which 6 are currently FDA-approved (guanfacine, quinidine,
xylometazoline, oxymetazoline, fenoldopam, and ropinirole)
(10). Interestingly, of the 2200 drugs screened, around 30% dis-
played significant 5-HT2B antagonist activity (10), indicating
that 5-HT2B receptors represent a “promiscuous target” for
approved and candidate medications. Our discovery that ergot-
amine and other ergots displayed functional selectivity for -ar-
restin over G-protein signaling at 5-HT2B receptors (10) led to
the first structure-based explication of GPCR -arrestin-biased
signaling (11). The discovery that the 5-HT2B receptor was
responsible for the side effects of the appetite-suppressing
medications fenfluramine and dexfenfluramine (6 – 8) was thus
a seminal finding of immense public health importance, which
ensures that drugs under development will now be counter-
screened against the 5-HT2B receptor for significant agonist
activity before being advanced to clinical trials.
Simultaneously with the discovery that the side effects of
fenfluramine were due to the 5-HT2B agonist activity of its main
metabolite norfenfluramine (6 – 8), it became clear that its ther-
apeutic (anorectic) actions were due to norfenfluramine’s ago-
nist activity at the closely related 5-HT2C receptor (12). This led
to the prediction that 5-HT2C-selective agonists devoid of
5-HT2B agonist activity would represent safe and effective
appetite suppressants (13) and the discovery of the 5-HT2C-
preferring agonist lorcaserin, which was approved by the FDA
as the first new obesity medication in nearly 20 years in 2012
(14 –16). Taken together, this vignette underscores how an
understanding of both on-target and off-target actions of drugs
at a single subfamily of GPCRs, in this case the 5-HT2 serotonin
receptor family, can be crucial for successful drug discovery
efforts.
Chemical Informatics-based Approaches for
Genome-wide GPCR-based Discovery
The discovery of small molecule drug-like compounds that
interact with GPCRs in a number of ways (e.g. as orthosteric,
allosteric, or biased ligands) is now relatively straightforward
and will not be reviewed in any detail here as there are a number
of excellent and recent review articles (17–19). As these are
important concepts for GPCR drug discovery, however, they
will be briefly defined. Thus, orthosteric ligands are those that
occupy the site(s) of the native or natural ligand, whereas allos-
teric ligands occupy a site distinct from the orthosteric site (18,
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19). Additionally, it is now appreciated that GPCRs signal via
-arrestin and that this signaling is frequently independent of
canonical G-protein modes of signaling (17). Indeed, drugs that
preferentially signal via -arrestin are considered to be -arres-
tin-biased (17). For the remainder of the review, we will focus
on genome-wide approaches for GPCR-based discovery, high-
lighting both in silico and physical screening approaches for the
discovery of novel small drug-like small molecules acting at
GPCRs.
In silico approaches for discovering GPCR modulators typi-
cally take advantage of large chemical databases that annotate
the biological properties of small molecules. Table 2 lists a few
of the more popular and widely used databases. Essentially,
these databases have large lists of chemical compound names
and, typically, their chemical descriptors along with the biolog-
ical activity associated with these compounds. Most commonly,
as in the ChEMBL database and PDSP Ki database (KiDB),
which rely mainly on published data, the activity is encoded as a
Ki or EC50 value, whereas other databases (e.g. ChemBank and
PubChem) provide the raw data as well as fitted data parame-
ters. Utilizing the information from such databases, we and our
collaborators have successfully predicted novel GPCR targets
for known drugs (3, 20, 21) and have designed novel drugs tar-
geting GPCRs entirely in silico (22). Importantly, in these exem-
plars of this overall approach, the GPCR-centric predictions
were extensively validated both in vitro and in vivo in model
organisms such as worms (23), zebrafish (24), mice (3, 22), and
most remarkably, in humans (21).
All of these resources rely upon accurately curated, precise
data and, of the cited resources, ChEMBL and KiDB would
appear to be the most useful as the main source of their data is
from peer-reviewed publications. ChEMBL historically has
drawn its data from medicinal chemistry publications, although
the most recent version of ChEMBL also incorporates large
amounts of data from PubChem. KiDB obtains its data mainly
from non-medicinal chemistry publications (e.g. biochemistry,
cell biology, pharmacology, neuroscience, and so on). Examin-
ing ChEMBL, which is the largest of these resources, we find
that a large number of GPCR targets are under-annotated with
respect to both their biological function and the chemical mat-
ter with which they may interact (Fig. 1, A and B). As can be
seen, at least 50% of the non-olfactory GPCRs in the human
genome have had few publications associated with them based
on a search of PubMed conducted in mid-2013. Additionally,
more than 50% of the non-olfactory GPCRs in the human
genome had few annotated small molecules (Table 2; GPCR
Safari ChEMBL release 3.0). Indeed, of the 159 “orphan” GPCRs
in the ChEMBL database, only 5 had annotated small molecules
with documented bioactivity. Significantly, although ChEMBL
is a curated database, it misidentifies the synthetic ligand 3-
{4-[4-(2-cyanophenyl)-1-piperazinyl]butyl}-1H-indole-5-carboxa-
mide as the natural ligand for GPR35 (https://www.ebi.ac.uk/
chembl/sarfari/gpcrsarfari/report/protein/266), even though
kynurenic acid has been proposed as a naturally occurring
ligand for GPR35 (25, 26). This example of GPR35 being mis-
annotated illustrates three important points: first, the need for
careful expert curation; second, the fact that all of these data-
bases contain a significant number of errors that could lead
investigators astray; and third, the value of orthogonal (i.e.
assays for which the readouts are independent) assays to vali-
date “hits” and presumed active compounds.
In Fig. 2, we show that most of the non-olfactory human
GPCR-ome is un-interrogated with respect to the chemical
matter as annotated in ChEMBL. The practical impact of this is
that, when using a database such as ChEMBL for predicting on-
and off-target actions of small molecules, most of the GPCR-
ome is hidden from a cheminformatics perspective. GPCRs are
not unique in that most of them are understudied, as a similar
conclusion was reached for kinases a few years ago (27). Indeed,
Isserlin et al. (28) have described what they have dubbed the
“Harlow-Knapp (H-K) effect,” which they define as: “the pro-
pensity of the biomedical and pharmaceutical research com-
munities to focus their activities, as quantified by the number of
publications and patents, on a small fraction of the proteome.”
Isserlin and colleagues (27, 28) noted that this was true for the
targets they studied (kinases, nuclear hormone receptors, and
ion channels) irrespective of whether they confined their bibli-
ographic analysis to the “pre-genomic era” (i.e. prior to the pub-
lication of the draft human genome in 2000) or later dates (i.e.
2009). We performed a different type of analysis and re-inter-
rogated the publication records for the druggable, non-olfac-
tory GPCRs in 2014, and compared this with all publications
predating 2013. As shown in Fig. 3, there was a similar although
not identical trend, with most of the understudied GPCRs still
being understudied and the more popular GPCRs continuing
this trend.
TABLE 1
New molecular entities targeting GPCRs in 2014
MOR, -opioid receptor.
Drug name GPCR Indication Ref.
Tasimelteon MT1/MT2 melatonin receptor agonist Non-24-hour sleep-wake
disturbance
60
Droxidopa Adrenergic GPCRs Neurogenic orthostatic
hypotension
61, 62
Albiglutide GLP-1 glucagon-like receptor agonist Type 2 diabetes 63, 64
Vorapaxar PAR-1 thrombin receptor antagonist Acute chest pain secondary
to coronary artery disease
65
Olodaterol 2-Adrenergic receptor agonist Chronic obstructive
pulmonary disease
66
Suvorexant OX1/2 orexin receptor antagonist Insomnia 67
Naloxegol MOR-opioid receptor antagonist Opioid-induced constipation 68
Dulaglutide GLP-1 glucagon-like receptor agonist Type 2 diabetes 69
Netupitant/palonosetron
combination
NK1-neurokinin and 5-HT3 receptor antagonists (note
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For resources available to interrogate GPCRs from a chemi-
cal standpoint, such as PubChem and ChemBank, these data-
bases will essentially supply raw screening data with (in many
but not all instances) confirmatory concentration-response
curves from which estimates of potency and efficacy are
derived. For example, PubChem lists screens for a large number
of GPCRs and, from these screens, results for a handful of
orphan GPCRs have been published in peer-reviewed journals
(29 –31). These published findings have led to the discovery
that pamoic acid is a potent agonist for GPR35 via -arrestin
signaling (31), as well as the discovery of novel agonists and
antagonists for GPR55 (29, 30).
As should be clear from the foregoing, cheminformatics-
based approaches can be quite useful for predicting GPCR
targets for both known drugs and other small, perhaps drug-
like, molecules. Because the bulk of the GPCR-ome is rela-
tively uncharted territory, i.e. because very few drug-like
small molecules have been identified for a large number of
human GPCRs, such studies are necessarily and unavoidably
underpowered.
Physical Approaches for Interrogating the GPCR-ome
In the past, we and others have used both radioligand binding
and functional assays to elucidate the ligand-based pharmacol-
ogy of non-orphan GPCRs. This approach, which we dubbed
“receptorome screening,” and which has been extensively
described in prior reviews (17, 32–34), has led us to a number of
important discoveries including: the identification of the -opi-
oid receptor as the site of action of the widely abused halluci-
nogen salvinorin A (35); the discovery that the 5-HT2B sero-
tonin receptor is the valvulopathy receptor (6); identification of
the remarkably complex pharmacology of antipsychotic drugs
(36); large-scale validation of cheminformatics predictions (3,
22); identification of GPCR as high affinity off-targets of kinase
inhibitors (37–39); and large-scale validation of computation-
ally docked and crystallography-confirmed binding poses (11,
40 – 48)
As radioligand-based approaches require radioligands with
high specific activity and high affinity for their targets, they are
not useful for the vast majority of GPCRs, for which such radio-
ligands are unavailable. Additionally, the physical, informatics,
TABLE 2
Useful cheminformatic, chemical biology, and pharmacology databases
Database acronyma URL Typeb Ref. Downloadablec
ChEMBL https://www.ebi.ac.uk/chembl/ C, T, ID 71 Y
KiDB; PDSP Ki
Database
http://pdsp.med.unc.edu/kidb.php C, T, ID (limited) 72 Y




http://sea.bkslab.org/ C, T, ID 3, 20 N but predictions
can be made
PubChem https://pubchem.ncbi.nlm.nih.gov/ C, T, ID 74 Y
IUPHAR GPCR
Database
http://www.guidetopharmacology.org/GRAC/ReceptorFamiliesForward?typeGPCR C, T Y
a Where applicable, name comes after semicolon.
b C, chemical; T, target; ID, chemical identifiers.
c Y  yes; N  no.
FIGURE 1. Many GPCRs are understudied. A, shown is a graph of PubMed publications for the non-olfactory GPCRs. For this graph, the time period studied was
up to and including August 2013. For searching for publications referencing a particular GPCR, either the International Union of Basic and Clinical Pharmacol-
ogy (IUPHAR)-approved name or the genome identifier was used, depending upon which resulted in the largest number of publications. B, many GPCRs have
no identified chemical modulators. Shown is a graph of CheMBL compounds culled from GPCR SARfari (https://www.ebi.ac.uk/chembl/sarfari/gpcrsarfari)
using version 3.00.
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and infrastructure requirements required to routinely screen
more than a few GPCRs simultaneously using radioligand bind-
ing assays are beyond the resources of most academic and
industrial laboratories. Fortunately, the National Institute of
Mental Health’s Psychoactive Drug Screening Program
(NIMH-PDSP), which is housed in the authors’ laboratory, pro-
vides screening as a free service to not-for-profit investigators,
thereby making this resource available to a large part of the
scientific community. Indeed, in the past 5 years, more than 500
investigators world-wide took advantage of the NIMH-PDSP
for GPCR profiling of novel and candidate drug-like small
molecules.
Functional screening methods are an alternative to radioli-
gand binding-based approaches. Unfortunately, there are cur-
rently no published approaches suitable for interrogating the
entire olfactory and non-olfactory GPCR-ome. Indeed, screen-
ing the entire druggable GPCR-ome is technically challenging
due to the diverse G-protein-mediated signaling cascades used
by GPCRs (e.g. Gs, Gi, Gq, or G12/13). In the past, forced coupling
of Gs, Gi, and G12/13 G-proteins to a Gq-like Ca2 readout has
been frequently used (49, 50) to identify ligands for orphan
and/or sparsely annotated GPCRs (17, 51). Approaches that
FIGURE 2. The GPCR tree is (mainly) un-interrogated. Shown in tree-based format are the data from Fig. 1B plotted on the GPCR tree (courtesy of V. Katritch
and R. C. Stevens—Scripps/USC).
FIGURE 3. Understudied GPCRs continue to be understudied. Shown is a
comparison of publications for individual GPCRs up to August 2013 (red) and
for the entire year of 2014 (green; analysis performed March 2015). The verti-
cal axis (number of publications) here is shown in log2 format to include both
datasets on the same graph.
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rely on native coupling to known G-proteins have been success-
ful in identifying novel and selective ligands for orphan GPCRs
(52). Additionally, many GPCRs couple to G12 and G13. Inter-
estingly, the G12/13-dependent shedding of a membrane-bound
reporter protein (53) has been reported as a potential “univer-
sal” approach for both orphan and non-orphan GPCRs.
Other approaches have relied on platforms that take advan-
tage of G-protein-independent -arrestin recruitment because
nearly all GPCRs induce arrestin translocation (54). Many
methods have emerged to quantify GPCR--arrestin interac-
tions, including high content screening (HCS) (55), biolumi-
nescence resonance energy transfer (BRET) (56), and transcrip-
tional activation following arrestin translocation (TANGO)
(57). We have found the TANGO-based approach to be quite
useful for chemical interrogation of GPCRs (11, 40, 43, 58, 59).
Indeed, we have recently devised a genome-wide approach
using a TANGO-based readout to screen nearly all of the drug-
gable GPCR-ome in a facile, simultaneous, and parallel manner
(47).
Conclusions and Recommendations
As we have shown, although GPCRs represent a useful and
important target class for therapeutic drug discovery and bio-
chemical study, most are under-interrogated. In part, this stems
from the lack of robust and scalable ways to assess their activi-
ties. New technological platforms are becoming available that
allow for unbiased interrogation of the druggable GPCR-ome
(47), and when these are made freely available, they will likely
begin to have a transformative effect on the study of GPCRs.
Additionally, because of the “Harlow-Knapp effect,” many
GPCRs will likely remain understudied despite their potential
importance from both a basic science as well as a translational
perspective.
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